Non Invasive Prenatal Testing Market to Hit Around USD 11.24 Bn By 2033
The global non invasive prenatal testing market size was exhibited at USD 4.30 billion in 2023 and is projected to hit around USD 11.24 billion by 2033, growing at a CAGR of 10.09% during the forecast period of 2024–2033.
Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/7533
Key Takeaways:
The increasing demand for non invasive prenatal testing (NIPT), rising collaborations & licensing agreements, and improvements in the reimbursement scenario are some of the key factors estimated to fuel market growth. Further, the proliferating incidence of chromosomal abnormalities is expected to accelerate market growth. The market was slightly impacted by the COVID-19 pandemic. Several manufacturing companies maintained regular communication with the U.S. FDA to keep themselves informed of any supply chain disruptions.
Of all the countries, there is a substantial opportunity in China for noninvasive prenatal screening, with nearly 14.65 Million annual births and an increasing number of high-risk pregnancies. In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue.
Furthermore, key manufacturers are undertaking several efforts to provide advanced products in the market. Test manufacturers offer other testing options such as tests for copy number variants, rarer trisomies, and microdeletions, including 11q deletion (Jacobsen syndrome), 22q11.2 deletions (DiGeorge syndrome), 15q deletion (Prader–Willi and Angelman syndromes), 15p deletion (cri-du-chat syndrome), and 4p deletion (Wolf–Hirschhorn syndrome. For instance, in May 2023, ARUP Laboratories launched a new cfDNA test with higher sensitivity and specificity compared to other NIPTs. The test is approved for screening pregnant women carrying a single fetus, and it can be performed as early as 10 weeks of pregnancy.
The market is highly saturated with existing key players operating in the NIPT market. Companies are forming partnerships and collaborations to maintain a stable position in the market. For instance, in January 2023, QIAGEN and Atila BioSystems collaborated to provide NIPT solutions to boost the application portfolio of its digital PCR platform QIAcuity. Moreover, in June 2021, Illumina entered into a strategic collaboration with Next Generation Genomic to introduce a CE-IVD, NGS-based NIPT test, VeriSeq NIPT Solution v2 in Thailand. With this initiative, Illumina aimed to have greater patient access to NIPT's next-generation sequencing.
Furthermore, these entities allow cross-selling of NIPTs with an array of other procedures, including carrier screening and preimplantation screening for in vitro fertilization. To provide the aforementioned services, players are collaborating with entities operating in parallel markets and other laboratories to gain significant market share. For instance, in August 2023, LGC Clinical Diagnostics extended and expanded its partnership with the Stanford University Department of Obstetrics and Gynecology for NIPT reference materials.
Market Dynamics
Improving reimbursement policies for average and low-risk pregnancies is expected to drive the adoption of noninvasive prenatal screening tests. For instance, in the U.S., Medicaid programs cover noninvasive prenatal tests for high-risk patients after first-trimester screening. NIPT is covered by insurers for around 114 Million women with average-risk singleton pregnancies in the U.S. Moreover, Australia & many European countries cover NIPT for average-risk women for primary screening. Such initiatives are anticipated to increase the adoption rate of NIPT procedures. Furthermore, improvement in reimbursement policies and the inclusion of NIPT in national health programs across the globe are encouraging market players to conduct R&D activities to develop novel tests.
Segments Insights:
Gestation Period Insights
The 13-24 weeks segment held the largest share of over 53.0% of the non invasive prenatal testing market in 2023. This can be attributed to the fact that maximum non-invasive prenatal procedures are carried out in the second trimester of pregnancy, and these tests also cover major complementary tests, such as ultrasound & serum screening for alpha-fetoprotein.The rapid adoption of cell-free DNA tests performed in the second trimester or after 10 weeks of pregnancy is one of the major factors propelling the segment. Post 10 weeks of pregnancy, there should be enough fetal DNA in the patient’s bloodstream, which can increase the adoption of cfDNA NIPTs in the second trimester of the pregnancy.
Technology Insights
Next-generation Sequencing (NGS) accounted for the largest revenue share of market in 2023. With the increase in NGS popularity, the market is becoming fiercely competitive. Illumina, Inc., Ariosa Diagnostics, Inc.; Verinata Health, Inc.; Natera; Sequenom, Inc.; Berry Genomics Co.; BGI; GENNET; and LifeCodexx AG are among the key companies that offer NGS-based NIPT testing for common chromosomal conditions. In addition, a 2021 NCBI article on a study based on 13,607 cases concluded that NGS NTP offers high sensitivities and specificities of more than 98.89%, and the failure rate is less than 0.72% in aneuploidy conditions such as trisomy 21, trisomy 18, trisomy 21 + 13, trisomy 13, & monoso
Pregnancy Risk Insights
The high and average risk segment accounted for the largest revenue shareof the market in 2023. This can be attributed to the growing adoption of these tests in high-risk cases and pregnancies in women 35 years and above. The market is well-penetrated for high-risk pregnancy tests. However, few payors do not have favorable medical coverage for average risk testing. Average risk guideline inclusion in the reimbursement for NIPT procedures is expected to serve as a high-impact rendering driver for this vertical in the coming years.
Method Insights
The cell-free DNA in maternal plasma tests segment accounted for the largest revenue share? of the market in 2023. Technological advancements have expanded the range of testing to whole genome sequencing, and they can detect many additional chromosomal anomalies, such as microdeletions & sex chromosomal abnormalities. For instance, the Panorama prenatal test by Natera Inc. helps detect sex chromosomal abnormalities, microdeletions, and triploidy. Moreover, this segment is anticipated to witness lucrative growth owing to a high number of product launches and the increasing adoption rate due to improving reimbursement scenarios.
Regional Insights
North America dominated the market with a revenue share of 43.0% in 2023, followed by Europe. The rapid development of next-generation sequencing and reproductive genetics is a key factor driving regional growth. Testing programs have been widely implemented across the country, resulting in a larger revenue share of the region in the global market. Furthermore, the increasing number of domestic and global companies receiving U.S. patents for commercializing NIPT tests is driving the revenue in the region. Furthermore, significant technological advancements, an increasing number of FDA approvals for NIPTs, and competition among biotechnology companies are projected to boost market growth over the forecast period.
Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to the rising maternal age, which contributes to the growing incidence of chromosomal aneuploidies in babies, leading to a rise in the potential customer base. Significant developments in China and Japan, technological integration of NGS procedures, and improving healthcare infrastructure are expected to boost regional growth.
Key Companies & Market Share Insights
Key players in the NIPT market are undertaking various strategies in order to strengthen their geographic presence and provide services across the globe.
Some of the prominent players in the non-invasive prenatal testing market include:
领英推荐
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global non invasive prenatal testing market.
Gestation Period
Pregnancy Risk
Method
Technology
Product
Application
End-use
By Region
Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/7533 ?
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333
About US
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Connect with Us
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
·??????? IND Address: 2nd Floor,Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045
·??????? Call: USA - +1 650 460 3308 | IND - +91 8793322019 | Europe +442080772818
·??????? [email protected]